Abstract
Following on from the publication of clinical practice guidelines [1], the European Association for the Study of the Liver (EASL) organized a 2-day conference focused on the management of hepatocellular carcinoma (HCC). Over 700 delegates convened in Geneva in mid-February 2014. This report selects a few important points that were discussed at the meeting. In comparison to other tumors, where the use of biomarkers has become routine in guiding clinical practice, none of them are used in HCC and the field is lagging behind. Several groups have published molecular classifications of HCCs, which are informative, and help us better understand the biology of HCC. Fortunately, different groups, using different samples, have identified the same HCC classes. The two common classes are characterized by:
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
